Insights from the Apixaban vs. Aspirin for Subclinical Atrial Fibrillation Trial.

The article focuses on the ARTESiA trial, specifically examining the role of CHA2DS2VASc scores in guiding the use of apixaban versus aspirin in patients with subclinical atrial fibrillation (SAF). It explores how these scores help stratify patients to determine who would benefit most from oral anticoagulation (OAC) to prevent stroke, balancing this against the increased risk of major bleeding associated with apixaban.